Surface Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced CEO Rob Ross will speak at two investor conferences. The first is a fireside chat at Cowen's 3rd Annual Virtual Oncology Innovation Summit on June 2, 2022, at 10 a.m. ET, followed by a corporate presentation at the Jefferies Healthcare Conference on June 9, 2022, at 11 a.m. ET. Both events will be available via live audio and archived webcast on the company's website.

Surface Oncology focuses on developing antibody therapies targeting the tumor microenvironment, with a pipeline that includes clinical-stage programs targeting CD39 and IL-27.

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences:

• A fireside chat during Cowen's 3rd Annual Virtual Oncology Innovation Summit on Thursday, June 2, 2022, at 10 a.m. ET.
  
  
• A corporate presentation at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11 a.m. ET.
  

The live audio and subsequent archived webcast of the fireside chat and corporate presentation will be accessible from the Events & Presentations page of the company's website.

About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com

FAQ

What investor conferences is Surface Oncology participating in June 2022?

Surface Oncology will participate in Cowen's 3rd Annual Virtual Oncology Innovation Summit on June 2, 2022, and the Jefferies Healthcare Conference on June 9, 2022.

Who is the CEO of Surface Oncology?

Rob Ross is the CEO of Surface Oncology.

What time is Surface Oncology's fireside chat at the Cowen Summit?

The fireside chat at Cowen's Summit is scheduled for June 2, 2022, at 10 a.m. ET.

When will Surface Oncology present at the Jefferies Healthcare Conference?

Surface Oncology's corporate presentation at the Jefferies Healthcare Conference is on June 9, 2022, at 11 a.m. ET.

Where can I access the Surface Oncology conference presentations?

The live audio and archived webcasts of Surface Oncology's presentations will be available on their Events & Presentations page on the company’s website.